Is this the year that biotech stocks make a comeback? After a couple of tough years, the industry is off to a strong start in 2024. The SPDR S&P Biotech ETF, which tracks the industry index, has seen a nearly 13% increase year to date.
It’s still early in the year, so it’s uncertain if this momentum will continue. However, regardless of the industry’s performance, there are two biotech stocks that are worth considering for long-term investment: Regeneron Pharmaceuticals (NASDAQ: REGN) and Exelixis (NASDAQ: EXEL).
REGN Total Return Level Chart
1. Regeneron
Despite the struggles of many biotech stocks in recent years, Regeneron has consistently delivered strong returns and is expected to continue doing so.
One reason for this is that the U.S. Food and Drug Administration (FDA) has accepted Regeneron’s application for Dupixent as a treatment for COPD. Dupixent, a treatment for eczema co-marketed with Sanofi, has been a key driver of Regeneron’s growth…
2024-03-08 08:15:00
Article from finance.yahoo.com